Biocircuit Technologies Inc.

Biocircuit Technologies Inc., operating as Axion PNI, develops minimally invasive medical device technology for surgical and diagnostic applications and operates as a federal prime contractor and grant recipient focused on research commercialization and military-relevant applications, competing full-and-open with no set-aside designation across seven recent federal awards.

The Atlanta, Georgia-based for-profit manufacturer is structured as a parent company with a subsidiary, Ampera Inc. Biocircuit's core capability is microneedle array and microhook-based device engineering for surgical repair and in-situ diagnostics. The company's recent federal work splits between Department of Defense R&D and National Institutes of Health biomedical research. On the defense side, Biocircuit holds a $1.83 million Other Transaction IDV from DARPA awarded September 29, 2023, for the Microneedle Arrays for In-Situ Diagnosis of Electronic Systems (MAIDENS) program, which applies the company's tissue-interface expertise to real-time monitoring of electronic component health and failure prediction in defense systems. Biocircuit also received a $350 thousand definitive contract from DARPA on January 28, 2026, under the Embedded Entrepreneurship Initiative to commercialize DARPA-derived microneedle array technology for military and civilian applications, with completion targeted January 27, 2027 and optional Minimum Viable Product extension to twenty-four months.

On the NIH side, Biocircuit is developing two surgical device platforms. The National Institute of Neurological Disorders and Stroke awarded a Small Business Innovation Research Phase I grant of $379 thousand on August 10, 2026, through July 31, 2027, to optimize and validate Lymph Tape, a microhook-based device for simplified lymphovenous anastomosis in lymphedema treatment that operates on reversible mechanical connection similar to hook-and-loop fasteners, eliminating the need for microsutures. Phase II will encompass animal testing, regulatory pathway development, manufacturing establishment, and FDA 510K approval pursuit. The National Institute of Neurological Disorders and Stroke also funded Nerve Tape commercialization readiness; a Small Business Innovation Research Commercialization Readiness award issued September 22, 2023, and completing November 30, 2026, supports design transfer, supplier qualification, tooling development, and manufacturing scale-up for Nerve Tape, a sutureless nerve repair device using microscale nitinol hooks embedded in biologic wrap. A single sub-award under Virginia Commonwealth University (dated December 16, 2024) covers Nerve Tape assisted gap management in peripheral nerve repair.

Recent activity shows two awards in 2026 following a gap from 2024, with five awards (combined potential value $350 thousand) reaching ultimate completion inside the next twenty-four months, triggering recompete exposure. Biocircuit's customer base spans four distinct federal agencies with concentration in NIH programs (National Institute of Neurological Disorders and Stroke accounts for three awards) and DARPA (two awards with $2.2 million combined potential value). Combined dollars obligated across all awards total $18.9 million against combined potential value of $2.2 million, reflecting significant prior funding relative to near-term ceiling values.